Here are the S-3 shelf registrations from Processa Pharmaceuticals, Inc. (PCSA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow PCSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCSA filings page.
Processa Pharmaceuticals, Inc. (PCSA) seeks to register for resale by selling stockholders up to an aggregate of 306,574,202 shares of common stock. The total comprises 142,254,972 merger conversion shares, 163,774,679 private-placement conversion shares and 544,551 Tungsten conversion shares. Conversion of Series A preferred stock requires stockholder approval and is subject to each holder’s beneficial ownership limitations; converted shares may be offered only after conversion. Processa is not selling shares and will receive no proceeds from selling-stockholder resales.
The registration follows Processa’s completed acquisition of Vidya on July 28, 2026, and a private placement that closed July 30, 2026, from which Processa received approximately $200 million in gross proceeds. Vidya’s lead candidate, VT7208, is an orally available BTK inhibitor being advanced for food allergy, chronic spontaneous urticaria and multiple sclerosis. If the required stockholder matters and Nasdaq listing application are approved, Processa expects to change its name to Vidya Therapeutics, Inc. and trade as VDYA on the Nasdaq Capital Market.